AbbVie Inc. cotiza a 268.07 USD y tiene una capitalización bursátil de $473.7B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients w…
| Periodo | 2026-10 | 2026-07 | 2026-04 | 2026-02 |
|---|---|---|---|---|
| Real | — | $3.65 | $2.65 | $2.71 |
| Estimado | $3.83 | $3.61 | $2.67 | $2.65 |
| Sorpresa | — | +1.1% | -0.7% | +2.3% |
| Métrica | ABBV | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 70.2% | 57.0% | +13.2% |
| Operating Margin | 24.6% | -38.6% | +63.3% |
| Net Margin | 6.9% | -33.6% | +40.5% |
| FCF Margin | 29.1% | -13.9% | +43.0% |
| ROE | — | -40.4% | — |
| ROA | 3.1% | -32.0% | +35.2% |
| Current Ratio | 0.67 | 2.84 | -2.17 |
| Debt / Equity | -19.73 | 0.28 | -20.01 |